Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview
04 juin 2014 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 4, 2014) - Nuvilex, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's...
Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial
17 avr. 2014 08h45 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 17, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has once again delivered a major announcement as it advances its pancreatic cancer treatment toward late phase clinical...
Nuvilex Investors Should Read Between the Lines as Company Attracts World Renowned Oncologist
03 avr. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 3, 2014) - That loud noise you hear coming from Nuvilex, Inc. (OTCQB: NVLX) this week is the collective excitement of many investors after the company stated it...
Nuvilex Funding Has Investors Preparing for Milestone Announcements in Late-Phase Clinical Trials
03 mars 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Mar 3, 2014) - Nuvilex (OTCQB: NVLX) investors who have patiently waited for the R&D biotech to reach a point where late-phase clinical trials were a reality, are...
Chicago Investment Firm Assumes $27 Million Risk to Help Nuvilex Unseat Celgene and Eli Lilly
24 févr. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Feb 24, 2014) - Lincoln Park Capital (LPC) purchased 8 million restricted shares of Nuvilex, Inc. (OTCQB: NVLX) in exchange for an initial $2 million out of what can be...
Nuvilex's Pancreatic Cancer Treatment Readies to Challenge Eli Lilly and Celgene in Late-Phase Clinical Trials
19 févr. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Feb 19, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is a small biotech firm in Silver Spring, Maryland, that hopes to soon be mentioned with much larger biotechnology and...
Exosomes; Nano-Scale Bubbles Creating Waves in Diagnostics and Therapeutics
17 déc. 2013 08h30 HE
|
InvestorIdeas.com
NEW YORK, NY and POINT ROBERTS, WA--(Marketwired - Dec 17, 2013) - Investorideas.com, an investor news and research portal issues an exclusive sector snapshot on the rapidly growing exosome market...
Nuvilex to Answer Increasing Calls for Better Pancreatic Cancer Treatment Without Gemcitabine
16 déc. 2013 09h15 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Dec 16, 2013) - Nuvilex, Inc. (OTCQB: NVLX) may be just what the National Cancer Institute (NCI) and a growing number of doctors ordered - the company's late stage...
After Pancreatic Cancer, Eli Lilly and Nuvilex Could Battle Over Diabetes Treatment
05 déc. 2013 09h15 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Dec 5, 2013) - Eli Lilly & Co. (LLY) has parlayed its cancer drug Gemzar® or gemcitabine into well over $10 billion since it gained approval to treat advanced,...
Nuvilex, Inc. Reaches Unofficial Starting Line of Its Phase 3 Pancreatic Cancer Clinical Trials
05 nov. 2013 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Nov 5, 2013) - Nuvilex, Inc. (OTCQB: NVLX) made an announcement yesterday that should have investors excited that the company's Phase 3 clinical trials may have...